AFM Approves DSM-Firmenich Merger

The latest announcement includes key details of the DSM-Firmenich merger.
The latest announcement includes key details of the DSM-Firmenich merger.
C/O Firmenich

On May 31, 2022,  DSM and Firmenich announced that they would be entering into a merger.

The companies have now launched the exchange offer as part of their merger of equals to create DSM-Firmenich.

Related: DSM and Firmenich Announce Merger

Geraldine Matchett and Dimitri de Vreeze, co-CEOs of DSM, said, "We are entering the exciting next phase as we look to bring together DSM and Firmenich's complementary capabilities, likeminded and passionate people, and unite the heritages of two great and historic companies. DSM-Firmenich is set to become the leading creation and innovation partner in nutrition, beauty and well-being, capable of delivering enhanced growth and shareholder value creation through strong growth synergies, as well as an enhanced customer offering and an even greater positive impact across the world."

Gilbert Ghostine, CEO of Firmenich, added, "This merger is a transformational moment for the history of both businesses. DSM-Firmenich will be a global-scale partner, uniquely positioned to anticipate and better address the evolving needs of consumers by unlocking opportunities for our customers, and our people. Our two companies have an unrelenting commitment to their role in society with ESG at the core of everything we do, and I firmly believe that DSM-Firmenich will have a positive and measurable impact on people, climate and nature."

Key takeaways

  • The AFM has approved the offering circular, enabling the company to formally launch the exchange offer as part of the merger of equals between DSM and Firmenich to create DSM-Firmenich.
  • The Acceptance Period begins on November 23, 2022 and expires January 31, 2023, unless extended.
  • Under the exchange offer, the DSM shareholders will be entitled, subject to certain terms and conditions, to exchange each DSM ordinary share they hold for one newly issued DSM-Firmenich ordinary share (the offer consideration).
  • Following the transfer of the DSM ordinary shares tendered under the exchange offer against payment of the offer consideration (settlement) and the admission, all issued and outstanding ordinary shares in the capital of Firmenich will be contributed to the company against payment of an amount in cash and the issuance of DSM-Firmenich ordinary shares (the Firmenich contribution) (together with the admission and the exchange offer referred to as the transactions) to establish DSM-Firmenich, which will be a new creation and innovation partner in nutrition, beauty and well-being.
  • The managing board of DSM and the supervisory board of DSM (the DSM boards) unanimously support the transactions and recommend the exchange offer to the DSM shareholders for acceptance. The board of directors of Firmenich unanimously supports and recommends the transactions. The Firmenich shareholders have approved the transactions.
  • DSM issued a position statement setting out its position on the exchange offer (the position statement) and a convocation notice (including the agenda and explanatory notes thereto) to the DSM shareholders (the DSM convocation notice) in relation to the extraordinary general meeting of the DSM shareholders (the DSM EGM) on January 23, 2023, at which the transactions, including the exchange offer, will be discussed and the DSM shareholders will be requested to vote in favor of, amongst other things, approving the transactions.

Transaction highlights

  • DSM and Firmenich entered into a business combination agreement to establish DSM-Firmenich, a new creation and innovation partner in nutrition, beauty and well-being through a merger of equals (the merger).
  • The merger is to be effected through the exchange offer and the Firmenich contribution.
  • The business operations of the company and its affiliates (DSM-Firmenich) will be organized in four businesses, being Perfumery & Beauty, Food & Beverage / Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health.
  • DSM has undertaken to procure that each member of the DSM boards will tender their DSM ordinary shares directly or indirectly held or subsequently acquired by such member under the exchange offer and vote his or her DSM ordinary shares in favor of the resolutions with respect to the transactions (the transaction resolutions) at the DSM EGM.
  • DSM has undertaken to tender under the exchange offer part of the DSM ordinary shares it holds in treasury.
  • The central works council and European works council of DSM (the DSM employee representative bodies) have been informed about the transactions, including the exchange offer, and the recommendation of the DSM boards. The central works council has given a positive advice.
  • The exchange offer and the respective obligations of the company, DSM and Firmenich to effect the transactions, and for DSM to ensure that the company effects the transactions and declares the exchange offer unconditional, is subject to the fulfillment of the conditions as set out in the offering circular (the transaction conditions).
  • The exchange offer is subject to a minimum acceptance level of 95% of DSM's aggregate issued and outstanding ordinary share capital as at the acceptance closing date. This percentage will be automatically adjusted to 80% of DSM's aggregate issued and outstanding ordinary share capital as at the acceptance closing date if the transaction resolutions have been adopted and are in full force and effect on the acceptance closing date.
  • Completion of the transactions is currently expected in Q1 2023.

More in News